



---

## PRESS RELEASE

Tuebingen Biotech Company Again Awarded a Prize

### ***immatics* is laureate in the "2007 STEP Award"**

Tuebingen, November 30, 2007. Today *immatics biotechnologies*, a company dedicated to the development of peptide-based immune therapeutics for the treatment of cancers, announced to be laureate in the "2007 STEP Award" in the category "Processes".

5

The jury was particularly convinced by the exceptionally short pre-clinical development time. For its first product candidate – IMA901 against renal cell cancer – the company took merely 22 months from the analysis of the first tumor samples to commencing vaccination of first patients in a clinical study. Less than a year later  
10 *immatics* was able to conclude this phase 1 study with very promising results. At the end of September 2007, the company started an international Phase 2 study for the cancer vaccine IMA901.

The "STEP Award" is a competition for rewarding high-growth companies in Germany,  
15 Switzerland and Austria. The initiators, Infraseriv Hoechst and the F.A.Z. Institute, jointly pursue with renowned sponsors the aim of giving companies during their growth phase a significant stimulus for their successful development. Further information on "STEP Award" can be found under [www.step-award.de](http://www.step-award.de)

20

#### **About *immatics***

*immatics* ([www.immatics.com](http://www.immatics.com)) is an independent biopharmaceutical company dedicated to the  
25 development of innovative therapeutic vaccines for cancer therapy. *immatics'* product candidates are based on tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. In 2007, the company launched an international clinical phase 2 study on its lead product candidate, IMA901, for therapy of renal cancer. Another immunotherapeutic vaccine for the treatment of colorectal cancer, IMA910, will soon enter  
30 clinical development. In addition, several further peptide-based product candidates are currently undergoing preclinical development and form the basis for a rapidly growing product pipeline for combating major types of cancer.

Formed in the year 2000 as a spin-off from the Institute of Immunology at the University of  
35 Tuebingen, *immatics* has raised €54 million (US\$ 73 million) in total of venture capital funding and employs more than 50 people today. The members of the *immatics* Supervisory Board include Actelion co-founder Thomas Widmann (Chairman) as well as Friedrich von Bohlen, Christof Hettich (both with Dievini), Erich Schlick (Wellington Partners), Klaus Stoeckemann (3i) and GPC Biotech CSO Sebastian Meier-Ewert.

40

**Further information is available from**

45 Dr. Harpreet Singh  
*immatics* biotechnologies GmbH  
Paul-Ehrlich-Str. 15  
72076 Tuebingen  
Germany  
Tel. +49-7071-565125-12  
E-mail: [singh@immatics.com](mailto:singh@immatics.com)